BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 25606797)

  • 1. Reduced rate of cardiovascular death after cytomegalovirus prophylaxis in renal transplant recipients.
    Opelz G; Döhler B
    Transplantation; 2015 Jun; 99(6):1197-202. PubMed ID: 25606797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CMV mismatch does not affect patient and graft survival in UK renal transplant recipients.
    Johnson RJ; Clatworthy MR; Birch R; Hammad A; Bradley JA
    Transplantation; 2009 Jul; 88(1):77-82. PubMed ID: 19584684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytomegalovirus serostatus pairing and deceased donor kidney transplant outcomes in adult recipients with antiviral prophylaxis.
    Kuo HT; Ye X; Sampaio MS; Reddy P; Bunnapradist S
    Transplantation; 2010 Nov; 90(10):1091-8. PubMed ID: 20885340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytomegalovirus viraemia and mortality in renal transplant recipients in the era of antiviral prophylaxis. Lessons from the western Australian experience.
    Selvey LA; Lim WH; Boan P; Swaminathan R; Slimings C; Harrison AE; Chakera A
    BMC Infect Dis; 2017 Jul; 17(1):501. PubMed ID: 28716027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors for late-onset cytomegalovirus infection or disease in kidney transplant recipients.
    Jamal AJ; Husain S; Li Y; Famure O; Kim SJ
    Transplantation; 2014 Mar; 97(5):569-75. PubMed ID: 24398852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of cytomegalovirus prophylaxis with acyclovir on renal transplant survival.
    Abraham KA; O'Kelly P; Spencer S; Hickey DP; Conlon PJ; Walshe JJ
    Ren Fail; 2008; 30(2):141-6. PubMed ID: 18300112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacoepidemiology of cytomegalovirus prophylaxis in a large retrospective cohort of kidney transplant recipients with Medicare Part D coverage.
    Santos CA; Brennan DC; Saeed MJ; Fraser VJ; Olsen MA
    Clin Transplant; 2016 Apr; 30(4):435-44. PubMed ID: 26841129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytomegalovirus infection post-pancreas-kidney transplantation--results of antiviral prophylaxis in high-risk patients.
    Fallatah SM; Marquez MA; Bazerbachi F; Schiff JR; Cattral MS; McGilvray ID; Norgate A; Selzner M; Rotstein C; Husain S
    Clin Transplant; 2013; 27(4):503-9. PubMed ID: 23731387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduction in late onset cytomegalovirus primary disease after discontinuation of antiviral prophylaxis in kidney transplant recipients treated with de novo everolimus.
    Devresse A; Leruez-Ville M; Scemla A; Avettand-Fenoel V; Morin L; Lebreton X; Tinel C; Amrouche L; Lamhaut L; Timsit MO; Zuber J; Legendre C; Anglicheau D
    Transpl Infect Dis; 2018 Apr; 20(2):e12846. PubMed ID: 29360195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effectiveness of preemptive therapy with ganciclovir in recipients of renal transplants at high risk (R-/D+) for the development of cytomegalovirus disease].
    Aranda-Verástegui F; Alberú J; Soto-Ramírez LE; González-Aguirre H; Muñoz Trejo T; Mancilla E; Díliz H; Correa-Rotter R; Sierra-Madero J
    Rev Invest Clin; 2002; 54(3):198-203. PubMed ID: 12183888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of CMV prevention on long-term recipient and graft survival in heart transplant recipients: analysis of the Scientific Registry of Transplant Recipients (SRTR) database.
    Snydman DR; Kistler KD; Ulsh P; Bergman GE; Vensak J; Morris J
    Clin Transplant; 2011; 25(4):E455-62. PubMed ID: 21504474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytomegalovirus infection: its incidence and management in cytomegalovirus-seropositive living related liver transplant recipients: a single-center experience.
    Wadhawan M; Gupta S; Goyal N; Vasudevan KR; Makki K; Dawar R; Sardana R; Lal N; Kumar A
    Liver Transpl; 2012 Dec; 18(12):1448-55. PubMed ID: 22903934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytomegalovirus disease in lung transplantation: impact of recipient seropositivity and duration of antiviral prophylaxis.
    Hammond SP; Martin ST; Roberts K; Gabardi S; Fuhlbrigge AL; Camp PC; Goldberg HJ; Marty FM; Baden LR
    Transpl Infect Dis; 2013 Apr; 15(2):163-70. PubMed ID: 23230972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparing cytomegalovirus prophylaxis in renal transplantation: single center experience.
    Varga M; Remport A; Hídvégi M; Péter A; Kóbori L; Telkes G; Fazakas J; Gerlei Z; Sárváry E; Sulyok B; Járay J
    Transpl Infect Dis; 2005 Jun; 7(2):63-7. PubMed ID: 16150092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Late cytomegalovirus infection after oral ganciclovir prophylaxis in renal transplant recipients.
    Murray BM; Subramaniam S
    Transpl Infect Dis; 2004 Mar; 6(1):3-9. PubMed ID: 15225220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transplanting kidneys from CMV-seropositive donors to CMV-seronegative recipients is not associated with poorer renal allograft function or survival.
    McLaughlin K; Sandhu S; Wu C; Muirhead N; Hollomby D; Jevnikar A
    Nephrol Dial Transplant; 2005 Jan; 20(1):176-80. PubMed ID: 15572381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 24-week oral ganciclovir prophylaxis in kidney recipients is associated with reduced symptomatic cytomegalovirus disease compared to a 12-week course.
    Doyle AM; Warburton KM; Goral S; Blumberg E; Grossman RA; Bloom RD
    Transplantation; 2006 Apr; 81(8):1106-11. PubMed ID: 16641594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polymorphism in programmed cell death 1 gene is strongly associated with lung and kidney allograft survival in recipients from CMV-positive donors.
    Forconi C; Gatault P; Miquelestorena-Standley E; Noble J; Al-Hajj S; Guillemain R; Stern M; Hoffmann T; Prat L; Suberbielle C; Masson E; Cesbron-Gautier A; Gaudy-Graffin C; Goudeau A; Thibault G; Ivanes F; Guibon R; Kazma I; Lebranchu Y; Büchler M; Magnan A; Halimi JM; Baron C
    J Heart Lung Transplant; 2017 Mar; 36(3):315-324. PubMed ID: 27751774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Postlung transplant survival is equivalent regardless of cytomegalovirus match status.
    Russo MJ; Sternberg DI; Hong KN; Sorabella RA; Moskowitz AJ; Gelijns AC; Wilt JR; D'Ovidio F; Kawut SM; Arcasoy SM; Sonett JR
    Ann Thorac Surg; 2007 Oct; 84(4):1129-34; discussion 1134-5. PubMed ID: 17888958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytomegalovirus: occurrence, severity, and effect on graft survival in simultaneous pancreas-kidney transplantation.
    Ricart MJ; Malaise J; Moreno A; Crespo M; Fernández-Cruz L;
    Nephrol Dial Transplant; 2005 May; 20 Suppl 2():ii25-ii32, ii62. PubMed ID: 15814546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.